1
|
TURGEON JACQUES, MURRAY KATHERINET, RODEN DANM. Effects of Drug Metabolism, Metabolites, and Stereoselectivity on Antiarrhythmic Drug Action. J Cardiovasc Electrophysiol 2008. [DOI: 10.1111/j.1540-8167.1990.tb01065.x] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
2
|
Tacke R, Linoh H, Ernst L, Moser U, Lambrecht G, Mutschler E, Sarge S, Cammenga HK. Sila-Pharmaka, 371)Darstellung und Eigenschaften der Enantiomere der Antimuskarinika Sila-Procyclidin und Sila-Tricyclamol-iodid: Optisch aktive Silanole mit Silicium als Chiralitätszentrum2). ACTA ACUST UNITED AC 2006. [DOI: 10.1002/cber.19871200719] [Citation(s) in RCA: 46] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
3
|
Abstract
Most antiarrhythmic drugs fulfil the formal requirements for rational use of therapeutic drug monitoring, as they show highly variable plasma concentration profiles at a given dose and a direct concentration-effect relationship. Therapeutic ranges for antiarrhythmic drugs are, however, often very poorly defined. Effective drug concentrations are based on small studies or studies not designed to establish a therapeutic range, with varying dosage regimens and unstandardised sampling procedures. There are large numbers of nonresponders and considerable overlap between therapeutic and toxic concentrations. Furthermore, no study has ever shown that therapeutic drug monitoring makes a significant difference in clinical outcome. Therapeutic concentration ranges for antiarrhythmic drugs as they exist today can give an overall impression about the drug concentrations required in the majority of patients. They may also be helpful for dosage adjustment in patients with renal or hepatic failure or in patients with possible toxicological or compliance problems. Their use in optimising individual antiarrhythmic therapy, however, is very limited.
Collapse
Affiliation(s)
- Gesche Jürgens
- Department of Clinical Pharmacology, Copenhagen University Hospital, Copenhagen, Denmark.
| | | | | |
Collapse
|
4
|
Endoh Y, Atarashi H, Hayakawa H, Nagasawa K, Kishida H, Takano T. Clinical significance of wide QRS complexes at the termination of paroxysmal supraventricular tachycardias. J NIPPON MED SCH 2002; 69:525-33. [PMID: 12646984 DOI: 10.1272/jnms.69.525] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
BACKGROUND A wide QRS complex is not a rare electrocardiographic phenomenon at the termination of paroxysmal supraventricular tachycardia (PSVT), but no plausible underlying mechanism has yet been proposed. The purpose of the present study was to elucidate the frequency and the underlying mechanism of the wide QRS complexes at the termination of PSVT. METHODS We retrospectively reviewed 305 electrocardiograms (ECGs) from 100 patients, on which PSVT termination was recorded. The frequency of the wide QRS complexes was analyzed in 181 ECGs to avoid duplication, because there were 124 ECGs obtained from the same patients with same methods. The 181 ECGs were divided by morphology into three groups: Type A, termination with wide QRS complex without pause; Type B, wide QRS complex following initial pause after termination; Type C, wide QRS complex following the first narrow QRS after termination. RESULTS The wide QRS complex was recorded in 81/181 (44.8%) ECGs (Type A; 3/81 (3.7%), Type B; 44/81 (54.3%), Type C; 62/81 (55.6%) ) and its frequency was not dependent on the mechanism of PSVT. It was more frequently observed after a long pause, and was frequently induced by procedures that increase vagal tone, such as intravenous adenosine 5'-triphosphate administration (16/22: 72.7%) and vagal stimulation maneuvers (16/32: 50%). There were a total of 41 wide QRS complexes (44.6%) which had a preceding sinus P wave, out of a total of 92 wide QRS complexes in all three types. These 41 wide QRS complexes included 30/44 (68.2%) Type B wide QRS, and 11 (24.4%) Type C wide QRS complexes. CONCLUSION The aberrant conduction or escaped ventricular contraction was suggested to be the underlying mechanism of the majority of wide QRS complexes and ventricular premature contraction is less frequent.
Collapse
Affiliation(s)
- Yasumi Endoh
- First Department of Internal Medicine, Tama-Nagayama Hospital, Nippon Medical School, Tama-shi, Tokyo, Japan
| | | | | | | | | | | |
Collapse
|
5
|
Campbell TJ, Williams KM. Therapeutic drug monitoring: antiarrhythmic drugs. Br J Clin Pharmacol 1998; 46:307-19. [PMID: 9803978 PMCID: PMC1874159 DOI: 10.1046/j.1365-2125.1998.t01-1-00768.x] [Citation(s) in RCA: 52] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/1998] [Accepted: 04/02/1998] [Indexed: 11/20/2022] Open
Abstract
Antiarrhythmic agents are traditionally classified according to Vaughan Williams into four classes of action. Class I antiarrhythmic agents include most of the drugs traditionally thought of as antiarrhythmics, and have as a common action, blockade of the fast-inward sodium channel on myocardium. These agents have a very significant toxicity, and while they are being used less, therapeutic drug monitoring (TDM) does significantly increase the safety with which they can be administered. Class II agents are antisympathetic drugs, particularly the beta-adrenoceptor blockers. These are generally safe agents which do not normally require TDM. Class III antiarrhythmic agents include sotalol and amiodarone. TDM can be useful in the case of amiodarone to monitor compliance and toxicity but is generally of little value for sotalol. Class IV antiarrhythmic drugs are the calcium channel blockers verapamil and diltiazem. These are normally monitored by haemodynamic effects, rather than using TDM. Other agents which do not fall neatly into the Vaughan Williams classification include digoxin and perhexiline. TDM is very useful for monitoring the administration (and particularly the safety) of both of these agents.
Collapse
Affiliation(s)
- T J Campbell
- Department of Clinical Pharmacology, St Vincent's Hospital, Darlinghurst, NSW, Australia
| | | |
Collapse
|
6
|
|
7
|
Nakamura M, Xue Y, Eto K, Hashimoto K. Antiarrhythmic effects of optical isomers of disopyramide on canine ventricular arrhythmias. J Cardiovasc Pharmacol 1996; 27:368-75. [PMID: 8907798 DOI: 10.1097/00005344-199603000-00009] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Disopyramide is an effective class I antiarrhythmic drug and widely used for the treatment of arrhythmias, but it has anticholinergic side effects. In vitro studies demonstrated that dextrorotatory (D-) disopyramide has a stronger anticholinergic action, whereas the levorotatory (L-) isomer has a stronger Na channel blocking action. Because the antiarrhythmic mechanism of disopyramide suppressing digitalis- and two-stage coronary ligation-induced canine ventricular arrhythmias is the drug-induced Na channel block, we examined the antiarrhythmic efficacy of D- and L-disopyramide on two arrhythmia models. On ouabain-induced ventricular tachycardia (VT), L-disopyramide 3 mg/kg decreased the arrhythmic ratio (number of ectopic beats/total heart rate), whereas the same dose of the D-isomer was ineffective and a higher dose (5 mg/kg) was needed to suppress the arrhythmia. The effective plasma concentrations (IC50) decreasing the arrhythmic ratio to 50% of the control were 5.3 and 11.3 mu g/ml for L- and D-disopyramide, respectively. We obtained similar results using 24-h two-stage coronary ligation VT. The IC50 were 8.9 and 22.2 mu g/ml for the L- and D-isomers, respectively. Our results indicate that L-disopyramide is about twice as strong an antiarrhythmic drug as the D-isomer.
Collapse
Affiliation(s)
- M Nakamura
- Department of Pharmacology, Yamanashi Medical University, Japan
| | | | | | | |
Collapse
|
8
|
Eichelbaum M, Gross AS. Stereochemical aspects of drug action and disposition. ADVANCES IN DRUG RESEARCH 1996. [DOI: 10.1016/s0065-2490(96)80003-7] [Citation(s) in RCA: 85] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|
9
|
Vanhoutte F, Vereecke J, Carmeliet E, Verbeke N. Effects of the enantiomers of disopyramide and its major metabolite on the electrophysiological characteristics of the guinea-pig papillary muscle. NAUNYN-SCHMIEDEBERG'S ARCHIVES OF PHARMACOLOGY 1991; 344:662-73. [PMID: 1775199 DOI: 10.1007/bf00174750] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
Disopyramide, a Class Ia antiarrhythmic drug, is clinically used as a racemic mixture; R(-)disopyramide and S(+)disopyramide. The major metabolite in man is desisopropyldisopyramide: R(-)desisopropyldisopyramide and S(+)desisopropyldisopyramide. The effects of the four compounds were compared on the electrophysiological characteristics of the guinea-pig papillary muscle using the standard microelectrode technique. At an external K+ concentration of 5.4 mmol/l and a stimulation frequency of 1 Hz, S(+)disopyramide (20 mumols/l) increased action potential duration (APD) by more than 18%, while it was diminished by 6% in the presence of R(-)disopyramide. Resting membrane potential amounted to -87.1 +/- 0.5 mV (n = 14) and -85.6 +/- 1.2 mV (n = 10), respectively. Also a small but significant difference in effect on the maximal rate of depolarization was observed, R(-)disopyramide being more potent, related with a slower recovery of the maximal rate of depolarization. The enantiomers of the metabolite appeared to be three times less potent than those of the parent drug in their effect on the maximal rate of depolarization. The characteristics of the enantiomers of the metabolite correlated with those of the parent drug: also the R(-)enantiomer was more potent in decreasing the maximal rate of depolarization and caused more shortening of the action potential than the S(+)enantiomer. Time constants for onset and recovery of/from rate dependent block of the maximal rate of depolarization were dependent upon the external K+ concentration, both for the enantiomers of the parent drug and those of the metabolite. Onset slowed down while recovery accelerated when external K+ was increased. Time constants were lower for the metabolite. When stimulation interval was shortened, the effect on the maximal rate of depolarisation increased. Only for the metabolite statistical significant stereoselective differences were observed at all stimulation intervals. The effects on the action potential duration were dependent upon stimulation interval; for all enantiomers the action potential duration tended to be relatively (% of control) higher at short stimulation intervals than at large stimulation intervals. The effect on the maximal rate of depolarization was also voltage dependent, but no significant differences were observed between the enantiomers, for the parent drug as well as for the metabolite.
Collapse
Affiliation(s)
- F Vanhoutte
- Laboratory of Clinical Pharmacy, University of Leuven, Belgium
| | | | | | | |
Collapse
|
10
|
Hasselström J, Enquist M, Hermansson J, Dahlqvist R. Enantioselective steady-state kinetics of unbound disopyramide and its dealkylated metabolite in man. Eur J Clin Pharmacol 1991; 41:481-4. [PMID: 1761078 DOI: 10.1007/bf00626374] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
Disopyramide is provided as a racemic mixture of R and S enantiomers, which have different pharmacodynamic and pharmacokinetic characteristics. Five volunteers were given racemic disopyramide 100 mg and 200 mg t.d.s. in a cross-over design. Plasma and urine concentrations of disopyramide and its active metabolite monodesisopropyl-disopyramide (MND) were determined at steady state by an enantioselective HPLC method. Unbound drug in plasma was measured after ultrafiltration. There was enantioselective clearance of unbound disopyramide (0.39 l.h-1.kg-1 for R-disopyramide and 0.58 l.h-1.kg-1 for S-disopyramide after 100 mg t.d.s.). The enantioselectivity was due to differences in the metabolism of disopyramide to MND and in further non-renal clearance, and the renal clearance of disopyramide was not enantioselective. The in vivo protein binding of disopyramide, which was saturable for both enantiomers, was also enantioselective. The difference in binding of the two enantiomers was explained by a difference in apparent binding capacity rather than in apparent binding affinity. The renal clearance of S-MND was significantly higher than R-MND (0.29 and 0.19 l.h-1.kg-1, respectively, after 100 mg t.d.s.). The renal clearance of MND also showed a tendency to saturation at higher concentrations.
Collapse
Affiliation(s)
- J Hasselström
- Department of Clinical Pharmacology, Huddinge Hospital, Karolinska Institute, Stockholm, Sweden
| | | | | | | |
Collapse
|
11
|
Abstract
Three underappreciated concepts having an important impact on the use of antiarrhythmic agents having Class I activity are discussed. These are stereochemical influences on antiarrhythmic action, the modulated receptor theory, and pharmacogenetics. The stereoisomers of some antiarrhythmic agents behave differently in terms of their potency, disposition, and antiarrhythmic action. For example, the enantiomers of both tocainide and mexiletine are cleared at different rates, and those of disopyramide have opposite effects on repolarization. The modulated receptor theory suggests that the affinity of antiarrhythmic drugs to bind to a specific receptor on or near the sodium channel depends on whether the sodium channel is open, resting, or inactivated. Study of the interaction between the state of the sodium channel and the differing actions of the antiarrhythmic agents have provided evidence for synergistic drug combinations. Pharmacogenetics relates to the differences observed in drug metabolism among individuals, which can result in variations of two- to fourfold in clearance and plasma concentration in some cases. There is still much to learn about Class I antiarrhythmic agents. These concepts should lead to a better understanding of their actions and increase their utility.
Collapse
Affiliation(s)
- R L Woosley
- Department of Pharmacology, Georgetown University School of Medicine, Washington, DC 20007
| |
Collapse
|
12
|
Le Corre P, Gibassier D, Descaves C, Sado P, Daubert JC, Le Verge R. Clinical pharmacokinetics of levorotatory and racemic disopyramide, at steady state, following oral administration in patients with ventricular arrhythmias. J Clin Pharmacol 1989; 29:1089-96. [PMID: 2482304 DOI: 10.1002/j.1552-4604.1989.tb03284.x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Electrophysiological effects, antiarrhythmic activity and kinetics of levorotatory disopyramide (R(-) DP) and racemic disopyramide (equimolar mixture of R(-) DP and S(+) DP) were compared in patients with ventricular arrhythmias. This double blind cross-over randomized trial was achieved, at steady-state, following oral administration of 200 mg three times a day. In comparison with baseline values, electrophysiological data indicated that R(-) DP and racemic DP prolonged, significantly and similarly, PR interval (+11.7% and +10%, respectively, P less than .01), and QTc interval (+9.2% and +7%, respectively, P less than .001), while QRS interval was not significantly affected. The antiarrhythmic activity, assessed by percent reduction in ventricular extrasystoles frequency, showed a similar efficiency of levorotatory and racemic DP: 80% and 74%, respectively (P = .24). Ventricular tachycardias disappeared with both treatments in the three patients concerned. During the racemic period, the mean total plasma clearance, expressed as CL/F, of S(+) DP (114.6 ml/min), was significantly lower than that of R(-) DP (157 ml/min), (P less than .001). The mean total plasma clearance of R(-) DP, during the levorotatory period (163 ml/min), did not differ from the respective value determined during the racemic period (P = .32). During the racemic period, the stereoselective difference in total plasma clearances, which is not observed when DP enantiomers are administered separately, may result from an increase in unbound fraction of R(-) DP, due to the presence of S(+) DP, which is known to be a potent displacer of R(-) DP.
Collapse
Affiliation(s)
- P Le Corre
- Laboratoire de Pharmacie Galénique et Biopharmacie, Université de Rennes, France
| | | | | | | | | | | |
Collapse
|
13
|
Enquist M, Hermansson J. Comparison between two methods for the determination of the total and free (R)- and (S)-disopyramide in plasma using an alpha 1-acid glycoprotein column. JOURNAL OF CHROMATOGRAPHY 1989; 494:143-56. [PMID: 2584312 DOI: 10.1016/s0378-4347(00)82664-x] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Two different high-performance liquid chromatographic systems for the determination of the total and free (R)- and (S)-disopyramide (DP) in plasma and urine were compared. In method I a Nucleosil C8 column was coupled in series with an alpha 1-acid glycoprotein column. Method II consisted of two systems; a LiChrosorb Si 60 column was used for the determination of the racemic drug concentration and the R/S ratio was determined on an alpha 1-acid glycoprotein column. The recovery of (R)- and (S)-DP from plasma was greater than 97% in both methods. The precisions of the (R)- and (S)-DP determinations in plasma are high with both methods. The relative standard deviations for the determination of the free concentration do not exceed 6.5% at 1.59 micrograms/ml racemic DP. Method II is preferred as it can also be used to determine the concentration of (R)- and (S)-monodesisopropyramide. It is also easier to avoid disturbances from endogenous compounds in plasma samples with method II than with method I. It was observed that DP was incorporated into urine sediment during storage. A simple ultrasonic treatment of the urine samples was demonstrated to release DP from the sediment.
Collapse
Affiliation(s)
- M Enquist
- Apoteksbolaget AB, Central Laboratory, Department of Biomedicine, Stockholm, Sweden
| | | |
Collapse
|
14
|
Jamali F, Mehvar R, Pasutto FM. Enantioselective aspects of drug action and disposition: therapeutic pitfalls. J Pharm Sci 1989; 78:695-715. [PMID: 2685226 DOI: 10.1002/jps.2600780902] [Citation(s) in RCA: 329] [Impact Index Per Article: 9.4] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Affiliation(s)
- F Jamali
- Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Canada
| | | | | |
Collapse
|
15
|
Kroemer HK, Funck-Brentano C, Silberstein DJ, Wood AJ, Eichelbaum M, Woosley RL, Roden DM. Stereoselective disposition and pharmacologic activity of propafenone enantiomers. Circulation 1989; 79:1068-76. [PMID: 2713973 DOI: 10.1161/01.cir.79.5.1068] [Citation(s) in RCA: 80] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
Propafenone is an antiarrhythmic drug that produces a variable degree of beta-blockade in humans and is administered as a racemate. To examine the relative contribution of the individual enantiomers to pharmacologic effects seen during treatment with propafenone, we assessed the steady-state plasma concentrations of (+)-S-propafenone and (-)-R-propafenone in seven patients who were on long-term oral therapy, and we evaluated the electrophysiologic and beta-blocking properties of both enantiomers in vitro. The metabolism of propafenone is known to be polymorphic and to cosegregate with that of debrisoquine-4-hydroxylation. Among five patients with the extensive metabolizer phenotype (EM), the ratio of the area under the plasma concentration-time curve of (+)-S-propafenone to (-)-R-propafenone was 1.73 +/- 0.15 (mean +/- SD). In the other two patients, who had the poor metabolizer phenotype (PM), the concentrations of both enantiomers were elevated but the S/R ratios were similar to those seen in patients with EM. In canine cardiac Purkinje fibers, both enantiomers produced similar frequency-dependent depression of maximum upstroke of phase 0. In contrast, the affinity of the human lymphocyte beta 2-adrenoceptor was approximately 100-fold greater for (+)-S-propafenone (Ki, 7.2 +/- 2.9 nM) than for the (-)-R-enantiomer (Ki, 571 +/- 141 nM). We conclude that during long-term oral therapy, propafenone undergoes stereoselective disposition in patients with either EM or PM. beta-Blockade during propafenone therapy is likely related to accumulation of (+)-S-propafenone.(ABSTRACT TRUNCATED AT 250 WORDS)
Collapse
Affiliation(s)
- H K Kroemer
- Department of Medicine, Vanderbilt University, Nashville, Tennessee 37232
| | | | | | | | | | | | | |
Collapse
|
16
|
Krstulović AM. Racemates versus enantiomerically pure drugs: putting high-performance liquid chromatography to work in the selection process. JOURNAL OF CHROMATOGRAPHY 1989; 488:53-72. [PMID: 2654165 DOI: 10.1016/s0378-4347(00)82939-4] [Citation(s) in RCA: 27] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
In view of the current negative attitude towards pharmaceutical preparations containing two or more drug substances, it is not surprising that the stereoisomeric composition of drugs has become a key issue in their development, regulatory approval and marketing. As the requirements placed on the purity of drugs become more and more stringent, the question arises of whether a racemic mixture should be automatically considered as being 50% impure. The answer is complex and requires careful comparative evaluations of the activities, toxicities and pharmacokinetics of the two enantiomers. In addition to the risk-benefit factors, the cost-benefit factors should also be carefully weighed in order to reach a decision which will guarantee drug safety. Excessive development costs and an unnecessary regulatory burden resulting from systematic demands for enantiomerically homogeneous drugs can be avoided with very potent drugs administered at low dosages and low-potency drugs for which the "inactive" isomer is not considerably more toxic than the active isomer. Regardless of the final decision taken, during the preclinical and clinical drug development it is important to have analytical methods suitable for conducting pertinent studies. This paper discusses the importance of stereochemistry in drug development and the role of high-performance liquid chromatography as a pre-eminent tool for analytical and preparative enantioselective separations.
Collapse
|
17
|
Evans AM, Nation RL, Sansom LN, Bochner F, Somogyi AA. Stereoselective drug disposition: potential for misinterpretation of drug disposition data. Br J Clin Pharmacol 1988; 26:771-80. [PMID: 3242583 PMCID: PMC1386594 DOI: 10.1111/j.1365-2125.1988.tb05318.x] [Citation(s) in RCA: 57] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023] Open
Abstract
1. Although it is well recognised that the enantiomers of a chiral drug may possess different pharmacokinetic and pharmacodynamic properties, many studies dealing with chiral drugs which are administered as their racemates rely on non-stereoselective analytical techniques. 2. We present a theoretical analysis to illustrate the potential which exists for misinterpretation of drug disposition and plasma drug concentration-effect data generated for a racemic drug using a non-stereoselective assay. 3. It was shown that the use of such an analytical method can lead to the collection of data which may be both quantitatively and qualitatively inaccurate with respect to the individual enantiomers. For example, the clearance of the unresolved drug may indicate concentration- and time-dependence even though this pharmacokinetic process is concentration- and time-independent for each of the enantiomers. 4. The problems discussed emphasise the need to consider stereoselectivity in clinical pharmacological studies involving racemic drugs.
Collapse
Affiliation(s)
- A M Evans
- School of Pharmacy, South Australian Insitute of Technology, Adelaide
| | | | | | | | | |
Collapse
|
18
|
Abstract
Plasma concentration monitoring of antiarrhythmic agents is valuable, but it is often misused or overemphasized in therapeutic decision-making. There are strict requirements for its appropriate use that are often not met--for both the newer and even the conventional antiarrhythmic drugs. For maximum value, there must be a reliable, accurate relation between the plasma drug concentration and drug action, a relation closer than that between dosage and drug action. The time of sample collection is important--most guidelines are based on "trough" plasma concentrations measured after steady-state equilibrium has been achieved. The use of an accurate, sensitive and specific assay is crucial to the value of plasma concentration monitoring guidelines. However, for agents having active metabolites, monitoring the concentration of only the parent drug can be misleading and limits (but does not necessarily eliminate) the value of plasma concentration monitoring guidelines for these agents. Plasma concentration monitoring of most antiarrhythmic agents is of value for certain specific purposes: to determine compliance to antiarrhythmic therapy, to detect and analyze possible drug interactions, to assess the benefit to risk ratio for increasing the dose of a particular antiarrhythmic agent, to maintain a stable drug effect in the presence of a patient's changing clinical condition and, to a limited extent, to assess the role of an agent in causing an adverse drug reaction. The importance of understanding the assay methods currently in use, as well as how plasma concentration monitoring of individual antiarrhythmic agents is affected by the presence of active metabolites, optical isomers differing in their activity and variations in protein binding, is essential in interpreting data obtained from plasma concentration monitoring.
Collapse
Affiliation(s)
- R L Woosley
- Department of Pharmacology, Georgetown University School of Medicine, Washington D.C. 20007
| |
Collapse
|
19
|
Giacomini KM, Nelson WL, Pershe RA, Valdivieso L, Turner-Tamiyasu K, Blaschke TF. In vivo interaction of the enantiomers of disopyramide in human subjects. JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS 1986; 14:335-56. [PMID: 3772736 DOI: 10.1007/bf01059195] [Citation(s) in RCA: 57] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
Disopyramide, an antiarrhythmic agent, is marketed as a racemic mixture of two enantiomers. The racemic drug has unusual pharmacokinetic properties because of its concentration-dependent binding to plasma proteins in the therapeutic plasma concentration range. This study examined, in healthy subjects, the individual pharmacokinetic properties of both total and unbound d- and 1-disopyramide in plasma after intravenous administration of each enantiomer separately (1.5 mg/kg). Also investigated is the pharmacokinetics of total d- and 1-disopyramide in plasma after intravenous administration of a pseudoracemate. Both d- and 1-disopyramide are found to exhibit concentration-dependent binding to plasma proteins, with d-disopyramide being more avidly bound at lower concentrations. The stereoselective, concentration-dependent binding to plasma proteins resulted in distinct pharmacokinetic properties when the enantiomers were given together as the pseudoracemate. d-Disopyramide had a lower plasma clearance and renal clearance, a longer half-life, and a smaller apparent volume of distribution than 1-disopyramide. However, when the enantiomers were administered separately, there were no differences in the clearance, renal clearance, and volume of distribution between enantiomers calculated from either total or unbound drug concentrations. The results reveal an important pharmacokinetic interaction between the enantiomers of disopyramide when given as a racemic mixture, which may be dose-dependent and is not apparent upon administration of the enantiomers separately.
Collapse
|
20
|
Brown BS, Gorczynski RJ, Reynolds RD, Shaffer JE. Comparison of the parasympatholytic activity of ACC-9358 and disopyramide. Br J Pharmacol 1986; 87:87-95. [PMID: 3513881 PMCID: PMC1916896 DOI: 10.1111/j.1476-5381.1986.tb10160.x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023] Open
Abstract
ACC-9358 (N-[(3,5-di(pyrrolidinylmethyl)-4-hydroxy)benzoyl]aniline) is a newly developed analogue of changrolin, an antiarrhythmic agent used in the Peoples Republic of China. Since changrolin and other antiarrhythmic agents exert parasympatholytic activity which may limit their clinical usefulness, it was of interest to examine the parasympatholytic effects of ACC-9358. For comparative purposes we also studied the parasympatholytic activity of disopyramide. In guinea-pig isolated ileal strips, disopyramide, 3-30 microM, and ACC-9358, 100-300 microM, competitively antagonized carbachol-induced contractions with pA2 values of 5.78 and 4.17, respectively. In guinea-pig isolated right atria, disopyramide 3-30 microM, competitively antagonized methacholine-induced slowing of spontaneous beating with a pA2 value of 5.99 whereas ACC-9358, 3-300 microM, produced no significant muscarinic blockade in this preparation. Disopyramide (1.9-15 mg kg-1, i.v.), but not ACC-9358 (7.5-1.5 mg kg-1, i.v.), significantly increased rat pupil diameter in vivo. Disopyramide and ACC-9358 blocked vagal-induced reductions in heart rate in dogs anaesthetized with pentobarbitone. ED50 values were approximately 0.65 and 11.25 mg kg-1, respectively. We conclude that ACC-9358 possesses significantly less parasympatholytic activity than disopyramide.
Collapse
|
21
|
Hermansson J, Eriksson M, Nyquist O. Determination of (R)- and (S)-disopyramide in human plasma using a chiral alpha 1-acid glycoprotein column. JOURNAL OF CHROMATOGRAPHY 1984; 336:321-8. [PMID: 6530464 DOI: 10.1016/s0378-4347(00)85155-5] [Citation(s) in RCA: 40] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
The direct resolution and quantitation of (R)- and (S)-disopyramide, isolated from human plasma, was accomplished using a chiral alpha 1-acid glycoprotein column. A LiChrosorb RP-2 column (50 X 3.0 mm I.D.) was used as a precolumn. Phosphate buffer, pH 6.20, containing 2-propanol and N,N-dimethyloctylamine was used as mobile phase. The precision of the determination of (R)- and (S)-disopyramide in human plasma, expressed as the relative standard deviation, was 1.8% and 3.3% for (R)- and (S)-disopyramide, respectively, at a drug level of 0.5 micrograms/ml. In two subjects who received a single capsule of racemic disopyramide (150 mg), the plasma levels of the (R) isomer were about half those of the (S) isomer. The half-lives of (R)- and (S)-disopyramide were similar.
Collapse
|
22
|
Boyd A, Groen MB, Hindriksen B, Marshall RJ, Sleigh T, Winslow E, Zeelen FJ. Ent-16 alpha-methylamino-3-methoxy-1,3,5(10)-estratrien-17 beta-ol hydrochloride, a selective anti-arrhytmic enantiosteroid. Steroids 1982; 40:615-23. [PMID: 7187712 DOI: 10.1016/0039-128x(82)90002-2] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Abstract
The title compound and its antipode with natural steroid configuration were synthesized and tested. Both compounds showed equal potency as anti-arrhythmic compounds. An additional effect found for the steroid with natural configuration was its plasma cholesterol lowering activity in the rat. This suggests that enantiosteroids may have a more selective action than the steroids with natural configuration.
Collapse
|
23
|
Pollick C, Giacomini KM, Blaschke TF, Nelson WL, Turner-Tamiyasu K, Briskin V, Popp RL. The cardiac effects of d- and l-disopyramide in normal subjects: a noninvasive study. Circulation 1982; 66:447-53. [PMID: 7094252 DOI: 10.1161/01.cir.66.2.447] [Citation(s) in RCA: 46] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Abstract
Commercially available disopyramide is a racemic mixture of equal parts of dextrorotatory (d-) and levorotatory (l-) optical isomers. We studied the cardiac effects of i.v. administration of each isomer and the racemic mixture (dl-) in six normal males by digitized echocardiography, systolic time intervals and ECG. Both isomers and the racemic mixture produced equally marked dose-dependent negative inotropic effects (28.1 +/- 11.8% mean maximal reduction in fractional shortening of left ventricular dimension) and diastolic effects (28.6 +/- 24.1% mean maximal reduction in peak left ventricular filling rate). However, only the d-isomer prolonged QTc duration (by 13.6 +/- 5.2% at maximum, p less than 0.001 vs l-isomer). We conclude that disopyramide, in the doses used, produces marked adverse effects on left ventricle systolic and diastolic function in normal subjects independent of optical rotation. The production of these effects by the l-isomer without affecting QTc duration suggests different subcellular mechanisms for the myocardial depressant effects and some of the electrophysiologic effects of disopyramide.
Collapse
|